Clearmind Medicine Completes Patient Enrollment for AUD Trial
Ticker: CMND · Form: 6-K · Filed: Oct 21, 2025 · CIK: 1892500
Sentiment: neutral
Topics: clinical-trial, drug-development, healthcare, FDA
TL;DR
Clearmind Medicine just enrolled the last patient in its Phase I/IIa AUD trial, moving closer to testing its new alcohol disorder drug.
AI Summary
Clearmind Medicine Inc. announced on October 21, 2025, that it has enrolled the final patient for the first cohort of its FDA-approved Phase I/IIa clinical trial. This trial is investigating the efficacy of a novel treatment for Alcohol Use Disorder (AUD). The company is a foreign private issuer filing a Form 6-K report.
Why It Matters
This milestone signifies progress in the development of a potential new treatment for Alcohol Use Disorder, a significant public health issue, and moves the company closer to potential regulatory approval.
Risk Assessment
Risk Level: medium — Clinical trial progress is a key indicator, but the outcome of the trial and subsequent regulatory approvals remain uncertain.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- October 21, 2025 (date) — Press release date and filing date
- FDA (company) — Regulatory body approving the trial
- Alcohol Use Disorder (condition) — Indication being studied
FAQ
What is the specific drug or treatment being investigated by Clearmind Medicine for Alcohol Use Disorder?
The filing does not specify the name of the drug or treatment being investigated, only that it is for Alcohol Use Disorder.
What is the expected timeline for the results of this Phase I/IIa clinical trial?
The filing does not provide an expected timeline for the results of the clinical trial.
What is the significance of enrolling the 'last patient for the first cohort'?
This means the first group of participants in the trial has now been fully recruited, allowing the trial to proceed to the next stage of data collection and analysis for that cohort.
Where is Clearmind Medicine Inc. headquartered?
Clearmind Medicine Inc. is headquartered at 101 – 1220 West 6th Avenue, Vancouver, British Columbia.
What type of report is this filing?
This filing is a Form 6-K, which is a Report of Foreign Private Issuer.
Filing Stats: 286 words · 1 min read · ~1 pages · Grade level 12.5 · Accepted 2025-10-21 07:30:18
Filing Documents
- ea0261930-6k_clearmind.htm (6-K) — 12KB
- ea026193002ex99-1_clearmind.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-25-100535.txt ( ) — 30KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: October 21, 2025 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3